Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BIIB dropped $2.5B of its MC today due to LLY's failure.
LLY's MC reduced $8.3B today due to the failure of its Alz drug which could more or less reflect the potential minimum value of AVXL.
AVXL is the only boy in the town now after Lilly and others failed.
My guess is that probably they overlooked the statement in 8k on this issue.
Agree with you. The question is what we can do about it as a retailer investor.
Is dementia included in AD?
Perhaps dementia is the next indicator for A2-73.
New article come out from Insiderfinacial
http://www.insiderfinancial.com/anavex-life-sciences-corp-nasdaqavxl-misinformation-is-our-opportunity/117411/
TPIV's website is upgrading at moment. If one goes their website one can get
"Bandwidth Limit Exceeded
The server is temporarily unable to service your request due to the site owner reaching his/her bandwidth limit. Please try again later."
Let me explain little bit about how the shorts works. It is a computer controlled trading system. They can see you (black pool) but you can not see them. When the program sees an order in, it tries to move the SP higher and normal trader will catch the price and buy the share with higher price. When there is no order, they can sell the sp down from one account to another.
Blue, it really depends on how big the short hand is. It it has enough power and seems it has from the change of sp (30-5). However, with the development of the company the power of the short hand is limited now. They might have secondary offer to buy back.
James, totally agree with you. If one looks at the chart, it is obviously that someone tried hard to push it down and there is a Big resistance at 10.3.
Jimmy, nice observation. It is well known that MM can create patterns of charts to trap anyone (long and short) as far as they can make money. There seems no laws to prevent it happening.
One question to anyone who may be interested in, I noticed that the contents of the PR today seems little bit different with that some one obtained from the poster. Can anyone explain why?
The side effects of galantamine
https://www.drugs.com/sfx/galantamine-side-effects.html
That was my thought years ago.
What happened?
Did AZN sell its antibody business to Pfi?
fgb, totally agree with you. Although he did it legally but it does not necessarily means it is good for shareholders. The problem is not him but the law. NO laws to prevent it happening.
Well how much can a CFO do to prevent bankruptcy?
Phantom, I totally agree with you. One can look at the process of AVXL last year when it is uplisted on Nasdaq. The sp change from 0.5 to 1.5 then rs to 4:1. The highest sp is 14 after uplisted.
P2 for Rett would happen sooner than expected according to AVXL plan. Currently it is their first priority.
Profit taking.
Purely profit taking by traders.
Where is J&E and Chinaman?
Rocalinda, Thanks a lot. The info is very crucial to all the investors. Perhaps they should have a conference call.
That is absolutely correct. As I compared the data of TauRx p3 and 2-73 p2, the statistic value is similar though p2 do not have placebo arm.
Just want to clarify that there is no arm in the trial called 2-73 in the document alone though it may exist somehow.
He might since the MMSE in monotherpay is +4 not 0.
Comparison between TauRx p3 and A2-73 p2a/b as a monotherapy
Did some research. Here is the number comparison of the two trial results
TauRx A2-73
Time 15 months (60wks) 31wks
Patient# 135 7
Placebo 34 0
P# w drug 51 7
ADCS-ADL Placebo -6 n/a
Pt w drug 0 0 (no change comp. to wk 0)
MMSD n/a +4
ADAS-cog Placebo -6 n/a
Pt w drug 0 plus compared to wk 0
SideEffect diarrhea, dysuria mild dizziness
If we think the mono effect is real, A2-73 seems really stabilized the disease like TarRx.
Agree. Scientifically their statement is correct as the data is not very statistically meaningful.
Agree with you totally. My sense is p2/3 preparation is in process and will be started after a partnership and ODD p2 starts.
Hi frrol, Would you mind to point out which ADCS-ADL graph you are talking about in the poster? Thanks.
Little fishy.
How could you say the primary endpoint for p2 is not MTD but efficacy?
Definitely the author is shorting AVXL as stated at the end of article.
Agree with you. Not everyone understands it especially when some shorts are trying to confuse longs.
Missling has indicated that there was no difference between 273 alone and combo at the publication of 5 wk data. Now it probably shows that 273 alone is better than combo. This is a very good indication when negotiating with PFE, which is probably the first candidate for partnership.
If one thinks it through, it is obvious that the one who publicizes the stories of piano player and painter is likely the same shorts.
Would you like to explain why?